SCHEMBL7952260

SCHEMBL7952260

CCCCOc1ccc(S(=O)(=O)C2CC(C(=O)OCC)CCN2Cc2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.52
KCNH2 Q12809 4/20 0.51
HRH3 Q9Y5N1 3/20 0.49
NPC1 O15118 1/20 0.49
ALDH1A1 P00352 1/20 0.49
TSHR P16473 1/20 0.49
RAB9A P51151 1/20 0.49
KMT2A Q03164 3/20 0.48
PKM P14618 2/20 0.48
NPSR1 Q6W5P4 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MEN1 O00255 1/20 0.46
S1PR5 Q9H228 1/20 0.46
MMP1 P03956 1/20 0.45
MMP9 P14780 1/20 0.45
MMP13 P45452 1/20 0.45
ADAM17 P78536 1/20 0.45
MAPT P10636 1/20 0.45
EGFR P00533 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7624290 0.91 LTA4H (0.49) LTA4HKCNH2HRH3NPC1ALDH1A1
SCHEMBL7642974 0.91 KCNH2 (0.49) LTA4HKCNH2HRH3NPC1ALDH1A1
SCHEMBL7619211 0.91 S1PR5 (0.53) LTA4HHRH3NPC1RAB9AKMT2A
SCHEMBL7619864 0.87 CCR8 (0.50) ALDH1A1TSHRRAB9AKMT2APKM
SCHEMBL7505933 0.85 LTA4H (0.47) LTA4HKCNH2HRH3NPC1ALDH1A1
SCHEMBL27555705 0.85 S1PR5 (0.54) KCNH2HRH3NPC1ALDH1A1RAB9A
SCHEMBL6565485 0.85 L3MBTL1 (0.50) ALDH1A1KMT2APKMNPSR1L3MBTL1
SCHEMBL7987987 0.84 KCNH2 (0.59) LTA4HKCNH2HRH3NPC1ALDH1A1
SCHEMBL7555893 0.83 S1PR5 (0.53) HRH3ALDH1A1RAB9AKMT2AMEN1
SCHEMBL7509653 0.82 CCR8 (0.49) ALDH1A1KMT2AMEN1S1PR5MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6331563-B1 LOW MOLECULAR WEIGHT, NON-PEPTIDE INHIBITORS OF MATRIX METALLOPROTEINASES AND TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME; TREATING ARTHRITIS, TUMOR METASTASIS, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, INSULIN RESISTANCE WYETH HOLDINGS CORPORATION 2001-12-18 US disclosed